152 related articles for article (PubMed ID: 35368120)
21. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
22. MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death.
Truong E; Gornbein JA; Yang JD; Noureddin N; Harrison SA; Alkhouri N; Noureddin M
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2570-2577.e1. PubMed ID: 36813013
[TBL] [Abstract][Full Text] [Related]
23. Quantifying steatosis in the liver and pancreas with MRI in patient with chronic liver disease.
Vieira J; Amorim J; Martí-Bonmatí L; Alberich-Bayarri Á; França M
Radiologia (Engl Ed); 2020; 62(3):222-228. PubMed ID: 31932016
[TBL] [Abstract][Full Text] [Related]
24. MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis.
Runge JH; Smits LP; Verheij J; Depla A; Kuiken SD; Baak BC; Nederveen AJ; Beuers U; Stoker J
Radiology; 2018 Feb; 286(2):547-556. PubMed ID: 28915103
[TBL] [Abstract][Full Text] [Related]
25. Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy.
Chang JW; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
Gut Liver; 2021 Jan; 15(1):117-127. PubMed ID: 32066210
[TBL] [Abstract][Full Text] [Related]
26. Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study.
McDonald N; Eddowes PJ; Hodson J; Semple SIK; Davies NP; Kelly CJ; Kin S; Phillips M; Herlihy AH; Kendall TJ; Brown RM; Neil DAH; Hübscher SG; Hirschfield GM; Fallowfield JA
Sci Rep; 2018 Jun; 8(1):9189. PubMed ID: 29907829
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B.
Jeon MY; Lee HW; Kim SU; Kim BK; Park JY; Kim DY; Han KH; Ahn SH
Liver Int; 2018 Apr; 38(4):676-686. PubMed ID: 28865176
[TBL] [Abstract][Full Text] [Related]
28. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study.
Brouha SS; Nguyen P; Bettencourt R; Sirlin CB; Loomba R
Eur Radiol; 2018 Apr; 28(4):1345-1355. PubMed ID: 29058029
[TBL] [Abstract][Full Text] [Related]
29. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
Kim BS; Seo YS; Kim YS; Lee CH; Lee HA; Um SH; Yoo JJ; Kim SG; Suh SJ; Jung YK; Ahn SH; Han KH; Yim HJ; Kim SU;
J Gastroenterol Hepatol; 2018 Feb; 33(2):503-510. PubMed ID: 28666070
[TBL] [Abstract][Full Text] [Related]
30. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
[TBL] [Abstract][Full Text] [Related]
31. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy.
Idilman IS; Aniktar H; Idilman R; Kabacam G; Savas B; Elhan A; Celik A; Bahar K; Karcaaltincaba M
Radiology; 2013 Jun; 267(3):767-75. PubMed ID: 23382293
[TBL] [Abstract][Full Text] [Related]
32. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.
Thompson SM; Garg I; Ehman EC; Sheedy SP; Bookwalter CA; Carter RE; Roberts LR; Venkatesh SK
Br J Radiol; 2018 Dec; 91(1092):20180345. PubMed ID: 30074820
[TBL] [Abstract][Full Text] [Related]
33. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
[TBL] [Abstract][Full Text] [Related]
34. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
35. Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease.
Chen J; Martin-Mateos R; Li J; Yin Z; Chen J; Lu X; Glaser KJ; Mounajjed T; Yashiro H; Siegelman J; Winkelmann CT; Wang J; Ehman RL; Shah VH; Yin M
Alcohol Clin Exp Res; 2021 Oct; 45(10):2103-2117. PubMed ID: 34486129
[TBL] [Abstract][Full Text] [Related]
36. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis.
Shin SH; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
Liver Int; 2015 Mar; 35(3):1054-62. PubMed ID: 24930484
[TBL] [Abstract][Full Text] [Related]
37. Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B.
Wong SW; Chan WK; Mohamed R
J Viral Hepat; 2020 Dec; 27(12):1297-1305. PubMed ID: 32668489
[TBL] [Abstract][Full Text] [Related]
38. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B.
Lee YB; Ha Y; Chon YE; Kim MN; Lee JH; Park H; Kim KI; Kim SH; Rim KS; Hwang SG
Clin Mol Hepatol; 2019 Mar; 25(1):52-64. PubMed ID: 30360031
[TBL] [Abstract][Full Text] [Related]
39. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease.
Kim JW; Lee YS; Park YS; Kim BH; Lee SY; Yeon JE; Lee CH
Sci Rep; 2020 Feb; 10(1):2671. PubMed ID: 32060386
[TBL] [Abstract][Full Text] [Related]
40. Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
Li J; Lu X; Zhu Z; Kalutkiewicz KJ; Mounajjed T; Therneau TM; Venkatesh SK; Sui Y; Glaser KJ; Hoodeshenas S; Manduca A; Shah VH; Ehman RL; Allen AM; Yin M
Hepatology; 2023 Oct; 78(4):1200-1208. PubMed ID: 37080558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
